Loading...
XETR
ILM1
Market cap345mUSD
Jun 12, Last price  
11.70EUR
1D
-2.50%
1Q
-8.31%
Jan 2017
50.00%
Name

Medios AG

Chart & Performance

D1W1MN
P/E
23.78
P/S
0.16
EPS
0.49
Div Yield, %
—
Shrs. gr., 5y
10.38%
Rev. gr., 5y
29.51%
Revenues
1.88b
+5.51%
1,037,5731,375,01735,224000133,210,908253,636,644327,829,818516,804,827626,543,0001,357,408,0001,610,777,0001,784,703,0001,883,038,000
Net income
13m
-33.29%
00000004,134,3314,326,8449,759,8545,525,0007,402,00018,329,00018,810,00012,548,000
CFO
74m
+349.01%
-3,700-80,6000103,36113,300-99,638-1,582,000816,000-3,135,563-449,286-38,115,00061,520,00037,122,00016,406,00073,665,000
Earnings
Aug 11, 2025

Profile

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
URL
https://medios.ag/
IPO date
Jan 01, 1999
Employees
514
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,883,038
5.51%
1,784,703
10.80%
1,610,777
18.67%
Cost of revenue
1,748,920
1,684,287
1,509,946
Unusual Expense (Income)
NOPBT
134,118
100,416
100,831
NOPBT Margin
7.12%
5.63%
6.26%
Operating Taxes
9,304
10,560
9,492
Tax Rate
6.94%
10.52%
9.41%
NOPAT
124,814
89,856
91,339
Net income
12,548
-33.29%
18,810
2.62%
18,329
147.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
(53)
BB yield
0.01%
Debt
Debt current
31,148
2,493
2,469
Long-term debt
244,608
31,795
32,714
Deferred revenue
Other long-term liabilities
5,085
3,849
4,517
Net debt
169,757
(36,752)
(44,795)
Cash flow
Cash from operating activities
73,665
16,406
37,122
CAPEX
(4,738)
(1,207)
(5,064)
Cash from investing activities
(222,277)
(16,567)
(86,541)
Cash from financing activities
183,798
(8,012)
(39,799)
FCF
83,231
53,788
62,324
Balance
Cash
105,999
71,040
79,213
Long term investments
765
Excess cash
11,847
Stockholders' equity
103,909
89,661
448,045
Invested Capital
741,799
489,804
450,728
ROIC
20.27%
19.11%
23.66%
ROCE
16.88%
19.54%
21.14%
EV
Common stock shares outstanding
24,432
23,806
23,868
Price
13.22
-16.33%
15.80
-9.92%
17.54
-54.79%
Market cap
322,992
-14.13%
376,135
-10.15%
418,645
-46.48%
EV
492,749
339,383
373,850
EBITDA
165,406
121,456
123,079
EV/EBITDA
2.98
2.79
3.04
Interest
10,863
2,407
1,257
Interest/NOPBT
8.10%
2.40%
1.25%